Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
IKAS Industrial Automation is provides intelligent manufacturing solutions for IC manufacturing and packaging testing, LED, photovoltaic and other pan-semiconductor manufacturing industries. The company has developed ROPN industrial system modeling as the underlying technology, combined with artificial intelligence and big data, and developed more than 30 modular products for equipment maintenance, production scheduling and other links in the manufacturing process.
Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in developing biologics that modulate cytokine functions, particularly focusing on next-generation IL-2 complexes. These complexes selectively enhance effector T cell functions, acting as effective immune adjuvants with a broad therapeutic window. Anaveon's innovative compounds demonstrate significant preclinical efficacy against cancer, both as standalone treatments and in combination with other therapies. The company's mission is to transform cytokines into life-saving treatments for patients suffering from various diseases characterized by immune system dysfunction. Through its targeted approach, Anaveon aims to provide substantial therapeutic benefits to cancer patients and others affected by immune pathology.
LOQUS23 THERAPEUTICS
Seed Round in 2021
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.
Kedalion Therapeutics Inc. is an ophthalmic drug company based in Menlo Park, California, that specializes in developing innovative therapies for eye care. Founded in 2015, the company has created a technology that delivers topical ophthalmic drugs with a high degree of precision and accuracy. This method allows for comparable efficacy while reducing the required dosage by 80% compared to standard eye drops. Kedalion's approach not only enhances patient comfort and convenience during self-administration but also improves the side effect profile of the medications. By focusing on reducing the burden on healthcare systems and enhancing the experience for both healthcare professionals and patients, Kedalion Therapeutics aims to transform the landscape of ophthalmic treatments.
Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
Flywheel Exchange LLC develops cloud scale data management platform for medical imaging core facilities, and academic and clinical research teams. The company offers tools, such as the flywheel web interface, a graphical user interface; the flywheel command line interface for uploading and downloading files, start jobs, and build gears; software development kits (SDK) for Python 2 and 3, Matlab, and R; and Flywheel Reaper for instrument integration. The company was incorporated in 2012 and is based in Minneapolis, Minnesota.
Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.
GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) to treat a range of conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and based in Boston, Massachusetts, with additional locations in Seattle and Israel, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs. This innovative approach aims to restore immune tolerance and address the limitations found in current regulatory T-cell therapies. The company was co-founded by experts in Treg biology and synthetic immunology, emphasizing its commitment to addressing the underlying causes of diseases linked to immune system dysfunction.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Soteria Biotherapeutics, Inc., founded in 2018 and based in San Francisco, California, specializes in the development of innovative immunotherapies for cancer treatment. The company is focused on creating next-generation conditionally active bispecific T-cell engaging antibodies aimed at addressing solid tumors. Utilizing its proprietary T-LITE™ platform, Soteria enables the small molecule-dependent activation of these bispecific antibody therapies. This approach allows for safer and more effective treatments, characterized by pulsatile activity that minimizes side effects and permits higher dosing levels for patients. Through its advancements, Soteria Biotherapeutics strives to improve the therapeutic options available for cancer patients.
Oculis is a clinical-stage biotechnology company dedicated to developing innovative topical treatments for ophthalmic diseases affecting both the anterior and posterior segments of the eye. Founded in 2003 and headquartered in Reykjavik, Iceland, Oculis utilizes a unique drug delivery platform that enhances drug absorption through a novel technique, enabling effective treatment of conditions such as diabetic macular edema, uveitis, chronic dry eye syndrome, glaucoma, and diabetic retinopathy with simple eye drops. This approach allows for non-invasive treatment of diseases at the back of the eye, traditionally requiring more complex methods, while also reducing the frequency of applications needed for anterior eye conditions. Oculis is committed to improving patient outcomes and enhancing the quality of life for individuals with vision-related health issues.
Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, founded in 2017. The company specializes in targeted protein degradation technology, which is aimed at developing innovative cancer therapeutics. Amphista's approach leverages the body's natural processes to selectively degrade and eliminate proteins that contribute to disease progression. By advancing next-generation therapeutics, the company seeks to improve treatment efficacy and enhance patient outcomes across a range of diseases. Amphista's research focuses on identifying novel methods to modulate the cell's degradation machinery, thereby addressing the underlying mechanisms of various conditions.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Faze Medicines is a biotechnology company established in 2020 and based in Cambridge, Massachusetts. The company focuses on developing small molecule drugs targeting the underlying drivers of disease pathology, particularly for conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines leverages innovative research on biomolecular condensates to create potential therapeutic breakthroughs. Through advanced screening and proteomics techniques, the company aims to pioneer new treatments for various diseases, including frontotemporal dementia (FTD) and DM1, thereby addressing significant unmet medical needs.
CatalYm GmbH, founded in 2016 and based in Munich, Germany, specializes in the development of immuno-oncology therapeutics. The company focuses on creating antibodies that target a placental factor known to be overexpressed in various tumor types. Through its innovative approach, CatalYm aims to enhance cancer treatment options and improve patient outcomes in the field of oncology.
Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), a vital enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage of creating a first-in-class series of molecules aimed at reactivating this key tumor suppressor. The firm employs proprietary development tools to facilitate rational drug design, aiming to provide therapeutic solutions for various cancer types and select non-oncology conditions.
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
E-Scape Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for neurodegenerative diseases. Established in 2015 and headquartered in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio is advancing a pipeline of therapeutics that target specific genetic drivers of these diseases, including ESB1609, a small molecule S1P5 receptor agonist for CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor designed for Parkinson’s disease patients with the LRRK2 G2019S variant. Additionally, the company is developing a program targeting ApoE4 in Alzheimer’s disease, emphasizing its commitment to precision medicine in treating genetically defined subpopulations.
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) to treat a range of conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and based in Boston, Massachusetts, with additional locations in Seattle and Israel, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs. This innovative approach aims to restore immune tolerance and address the limitations found in current regulatory T-cell therapies. The company was co-founded by experts in Treg biology and synthetic immunology, emphasizing its commitment to addressing the underlying causes of diseases linked to immune system dysfunction.
mPharma Data, Inc. is a technology-driven company based in Accra, Ghana, with an additional location in Lexington, Massachusetts. Founded in 2013, it focuses on improving access to high-quality medications in emerging markets by connecting physicians, pharmacies, and patients through its application. The company aggregates real-time market data on prescription trends, drug consumption, and adverse reactions, providing valuable insights to pharmaceutical manufacturers, distributors, and governments. mPharma offers a pharmacy network application that centralizes inventories from multiple pharmacies, enabling easier drug searches for physicians and patients. Additionally, the company provides subscription-based data analytics for actionable insights on drug consumption and diagnosis, along with prescription management tools to assist healthcare providers in locating various medicines. By partnering with drug manufacturers, insurance companies, and governments, mPharma aims to facilitate affordable access to essential medications for patients.
FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. It specializes in developing innovative therapeutics for cancer treatment by targeting key molecular pathways involved in DNA replication stress. The company aims to create first-in-class compounds that represent a novel approach in the fight against cancer, focusing on drugging specific molecular targets associated with this replication stress. Through its research and development efforts, FoRx Therapeutics seeks to contribute to the advancement of targeted anticancer drugs within the healthcare industry.
Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Arctos Medical
Seed Round in 2019
Arctos Medical is a spin-off company from the University of Bern and has developed a revolutionary gene therapy that does not correct rare genetic eye diseases but much more common cases of blindness.
Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative therapies aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology is designed to address a range of autoimmune and allergic diseases, including prevalent conditions such as celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens, Anokion’s approach provides precise therapies that minimize side effects and enhance patient outcomes in the treatment of autoimmune disorders.
Adicet Bio is a biotechnology company focused on the discovery and development of allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing its lead product candidate, ADI-001, which is a first-in-class allogeneic gamma delta T cell therapy designed to target CD20. This therapy aims to address relapsed or refractory aggressive B cell non-Hodgkin's lymphoma and potentially autoimmune diseases. Additionally, Adicet Bio is developing another preclinical candidate, ADI-270, which is an armored gamma delta CAR T cell therapy targeting renal cell carcinoma, with prospects for treating other solid tumors and hematological malignancies that express CD70.
Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia that specializes in developing gene therapies for cardiovascular diseases. Founded in 2013, Renovacor is focused on addressing dilated cardiomyopathy (DCM), a condition that affects over 3 million individuals in the United States. The company's lead program utilizes a recombinant adeno-associated virus (AAV) to create a gene therapy targeting patients with DCM caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This specific genetic mutation is estimated to affect around 35,000 individuals in the U.S. and a similar number in Europe, representing an orphan disease as defined by FDA guidelines. Patients with BAG3 mutations tend to be younger and experience a faster progression to advanced heart failure compared to those with ischemic heart disease. Currently, these patients receive standard heart failure treatments, but the five-year survival rate remains at only 50%. Renovacor aims to develop a BAG3 gene replacement therapy that could prevent disease progression in this vulnerable population.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, founded in 2013. The company specializes in the tissue-specific regulation of sex hormone effects and is focused on developing innovative treatments for urological and endocrinological diseases. Its lead product, Fispemifene, is a selective estrogen receptor modulator designed to address symptoms related to low testosterone in men. Additionally, Forendo is working on a 17HSD1-inhibitor aimed at treating endometriosis. By targeting specific hormone mechanisms, Forendo Pharma seeks to enhance treatment options for both male and female health conditions, addressing unmet medical needs in these areas.
Cala Health, Inc. is a bioelectronic medicine company focused on developing innovative therapies for chronic diseases. Based in Burlingame, California, the company specializes in wearable neuromodulation devices that utilize advancements in neuroscience and technology to provide individualized peripheral nerve stimulation. Its flagship product, Cala Trio, is a non-invasive therapy designed to offer relief from hand tremors in adults with essential tremor, a condition affecting millions. In addition to its current offerings, Cala Health is actively developing new therapeutic solutions in the fields of neurology, cardiology, and psychiatry, aiming to enhance the standard of care for patients with chronic conditions. Founded in 2013, the company has garnered support from prominent investors in both the healthcare and technology sectors.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in developing biologics that modulate cytokine functions, particularly focusing on next-generation IL-2 complexes. These complexes selectively enhance effector T cell functions, acting as effective immune adjuvants with a broad therapeutic window. Anaveon's innovative compounds demonstrate significant preclinical efficacy against cancer, both as standalone treatments and in combination with other therapies. The company's mission is to transform cytokines into life-saving treatments for patients suffering from various diseases characterized by immune system dysfunction. Through its targeted approach, Anaveon aims to provide substantial therapeutic benefits to cancer patients and others affected by immune pathology.
Athelas, Inc. develops and manufactures an innovative in-home blood diagnostic device designed to monitor the immune system using just a drop of blood. Founded in 2016 and based in Mountain View, California, the company's portable optical unit analyzes blood cells and generates diagnostic reports. This technology assists healthcare providers in early identification of conditions such as leukemia, infections, and inflammatory diseases, allowing patients to monitor their immunity levels conveniently from home. Athelas operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Occlufit AG is a Swiss company founded in 2018 and based in Zurich, specializing in the design and development of innovative cardiovascular occlusion solutions. Its flagship product, the Occlufit device, is engineered to conform to complex anatomical geometries, enabling it to provide immediate sealing of cardiovascular defects. This technology plays a crucial role in the early detection and treatment of cardiovascular diseases, addressing a significant need in the medical field. The company's focus encompasses various aspects of product development, including engineering, intellectual property, regulatory compliance, and clinical management, all aimed at advancing cardiovascular healthcare.
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and neurodegenerative diseases that are influenced by the classical complement pathway. The company’s research revolves around C1q, a key molecule that, when aberrantly activated, contributes to various disease processes. Its lead product candidates include ANX005, a monoclonal antibody designed for intravenous administration, which has completed Phase 1b trials for treating Guillain-Barré syndrome, and ANX007, formulated for intravitreal use, which has also completed Phase 1b trials aimed at glaucoma treatment. Additionally, Annexon is advancing preclinical candidates targeting conditions such as warm autoimmune hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis, and geographic atrophy. Founded in 2011 and headquartered in South San Francisco, California, the company employs a biomarker-driven strategy to ensure effective engagement of its therapies in the intended patient populations.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, founded in 2013. The company specializes in the tissue-specific regulation of sex hormone effects and is focused on developing innovative treatments for urological and endocrinological diseases. Its lead product, Fispemifene, is a selective estrogen receptor modulator designed to address symptoms related to low testosterone in men. Additionally, Forendo is working on a 17HSD1-inhibitor aimed at treating endometriosis. By targeting specific hormone mechanisms, Forendo Pharma seeks to enhance treatment options for both male and female health conditions, addressing unmet medical needs in these areas.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.
Enterprise Therapeutics is a drug discovery company dedicated to the research
and development of novel therapies for the treatment of respiratory diseases.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Zikani Therapeutics, Inc. develops and commercializes therapeutics for patients with limited treatment options. It offers TURBO-ZM, a platform to develop novel ribosome modulating agents (RMAs) for the treatment of cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Zikani Therapeutics, Inc. was formerly known as Macrolide Pharmaceuticals, Inc. and changed its name to Zikani Therapeutics, Inc. in February 2015. Zikani Therapeutics, Inc. was incorporated in 2014 and is based in Watertown, Massachusetts.
Oculis is a clinical-stage biotechnology company dedicated to developing innovative topical treatments for ophthalmic diseases affecting both the anterior and posterior segments of the eye. Founded in 2003 and headquartered in Reykjavik, Iceland, Oculis utilizes a unique drug delivery platform that enhances drug absorption through a novel technique, enabling effective treatment of conditions such as diabetic macular edema, uveitis, chronic dry eye syndrome, glaucoma, and diabetic retinopathy with simple eye drops. This approach allows for non-invasive treatment of diseases at the back of the eye, traditionally requiring more complex methods, while also reducing the frequency of applications needed for anterior eye conditions. Oculis is committed to improving patient outcomes and enhancing the quality of life for individuals with vision-related health issues.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
Aelin Therapeutics is a Belgian biotherapeutics company established in 2017 and headquartered in Heverlee. It specializes in developing innovative antibiotics and therapeutics through its proprietary Pept-in technology, which utilizes protein aggregation to achieve functional knockdown of target proteins. This platform is designed to address challenging medical conditions, including infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) and other undruggable targets in humans. The company was founded by VIB in collaboration with partner universities, including KU Leuven, VUB, and UGent, and is backed by extensive preclinical proof-of-concept data. Aelin Therapeutics' approach allows for the rational design of novel biotherapeutics, distinguishing itself from traditional therapeutic modalities by targeting intracellular spaces typically inaccessible to small molecules or antibodies. The technology's versatility extends beyond human applications, demonstrating efficacy against bacteria, cancer cells, fungi, viruses, and even plant cells.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
Neurovia, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, founded in 2013. The company focuses on developing therapies for neurological disorders, specifically targeting unmet medical needs associated with X-linked adrenoleukodystrophy (X-ALD). Neurovia's primary objective is to provide a treatment that can halt the progression of neurological deficits caused by this rare genetic disease. The company has developed a selective thyromimetic agent aimed at improving the quality of life for patients suffering from X-ALD.
E-Scape Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for neurodegenerative diseases. Established in 2015 and headquartered in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio is advancing a pipeline of therapeutics that target specific genetic drivers of these diseases, including ESB1609, a small molecule S1P5 receptor agonist for CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor designed for Parkinson’s disease patients with the LRRK2 G2019S variant. Additionally, the company is developing a program targeting ApoE4 in Alzheimer’s disease, emphasizing its commitment to precision medicine in treating genetically defined subpopulations.
Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through the advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays. It was founded in 2013 and is headquartered in San Francisco, California.
Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through the advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays. It was founded in 2013 and is headquartered in San Francisco, California.
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.
Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
Cavion LLC is a clinical-stage pharmaceutical company focused on developing therapies for neurological and rare genetic diseases by modulating T-type calcium channels (Cav3). The company’s lead product, CX-8998, targets these channels in the nervous system, and Cavion aims to deliver innovative non-opioid treatments for conditions such as neuropathic pain, essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. Founded in 2003 and based in Charlottesville, Virginia, with an additional office in Cambridge, Massachusetts, Cavion was previously known as Tau Therapeutics LLC until its name change in 2014. The company is notable for being the first to target Cav3 ion channels in the treatment of solid tumors, with ongoing Phase 1 clinical trials investigating its potential in brain cancer. Cavion's approach leverages advanced chemistry and clinical expertise to enhance the efficacy of existing therapies, such as chemotherapy and radiation, against solid tumor cancers. As of August 2019, Cavion operates as a subsidiary of Jazz Pharmaceuticals plc.
Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, founded in 2016, that focuses on developing orally available drugs for inflammatory diseases by targeting the inflammasome. The company's innovative approach aims to block inflammasome signals, addressing the underlying causes of inflammation. Inflazome's portfolio includes treatments for a range of conditions, such as orphan diseases like Muckle-Wells syndrome and familial cold autoinflammatory syndrome, as well as chronic inflammatory disorders affecting the central nervous system, including Alzheimer's, Parkinson's, and multiple sclerosis. The company also targets systemic inflammatory diseases like cardiovascular and gastrointestinal issues, and explores applications in oncology and dermatology. Inflazome operates as a subsidiary of Roche Holding AG.
ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and neurodegenerative diseases that are influenced by the classical complement pathway. The company’s research revolves around C1q, a key molecule that, when aberrantly activated, contributes to various disease processes. Its lead product candidates include ANX005, a monoclonal antibody designed for intravenous administration, which has completed Phase 1b trials for treating Guillain-Barré syndrome, and ANX007, formulated for intravitreal use, which has also completed Phase 1b trials aimed at glaucoma treatment. Additionally, Annexon is advancing preclinical candidates targeting conditions such as warm autoimmune hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis, and geographic atrophy. Founded in 2011 and headquartered in South San Francisco, California, the company employs a biomarker-driven strategy to ensure effective engagement of its therapies in the intended patient populations.
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.
Adicet Bio is a biotechnology company focused on the discovery and development of allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing its lead product candidate, ADI-001, which is a first-in-class allogeneic gamma delta T cell therapy designed to target CD20. This therapy aims to address relapsed or refractory aggressive B cell non-Hodgkin's lymphoma and potentially autoimmune diseases. Additionally, Adicet Bio is developing another preclinical candidate, ADI-270, which is an armored gamma delta CAR T cell therapy targeting renal cell carcinoma, with prospects for treating other solid tumors and hematological malignancies that express CD70.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.
Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.
Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics for diseases linked to the complement system's excessive activation. Utilizing a proprietary peptide chemistry platform, the company creates synthetic macrocyclic peptides that possess the specificity of antibodies and the advantageous properties of small molecules. Its primary product candidate, Zilucoplan, is an injectable treatment that has completed Phase II clinical trials for generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria, as well as a Phase Ib trial for patients with renal impairment. Ra Pharmaceuticals is also exploring pre-clinical programs targeting various complement factors for conditions such as C3 glomerulonephritis and autoimmune diseases. Additionally, the company has a collaboration with Merck & Co. to identify orally available cyclic peptides for cardiovascular targets. Founded in 2008, Ra Pharmaceuticals operates as a subsidiary of UCB SA.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.
Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area. The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation. ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.
Kanyos Bio was founded with the goal of developing antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease. Our technology originated at EPFL (Ecole Polytechnique Fédérale Lausanne) in Switzerland with our sister company, Anokion. Kanyos and Anokion are collaborating in this effort with Astellas Pharma, Inc. (“Astellas”). As an independent affiliate, Kanyos aims to develop antigen-specific, disease-modifying therapies for patients with type-1 diabetes and celiac disease by leveraging the immunotechnology expertise of Anokion and the clinical translation experience of Astellas.
Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Nabriva Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious bacterial infections. The company's lead product, lefamulin, is a semi-synthetic pleuromutilin antibiotic designed to treat community-acquired bacterial pneumonia and acute bacterial skin infections. It is currently undergoing clinical trials for additional applications, including pediatric infections, sexually transmitted infections, osteomyelitis, and prosthetic joint infections. Nabriva is also advancing CONTEPO, an epoxide antibiotic aimed at treating complicated urinary tract infections, and it is in clinical trials for peri-operative prophylaxis. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics has evolved from its earlier identity as a research institute focused on antibiotic development.
Aeglea BioTherapeutics is a clinical-stage biotechnology company focused on developing human enzyme therapeutics for rare genetic and cancer diseases. Its lead product candidate, pegzilarginase, is a recombinant human Arginase 1 enzyme currently undergoing Phase III trials to assess its safety and efficacy in treating Arginase 1 deficiency. The company's preclinical pipeline includes several innovative candidates: ACN00177 for homocystinuria, AEB5100 which degrades plasma cystine and cysteine, AEB2109 targeting the degradation of methionine, and AEB3103. Aeglea BioTherapeutics aims to exploit the amino acid dependencies of tumors by creating novel, human-derived enzymes that selectively target these vulnerabilities, differentiating the metabolic needs of tumor cells from those of normal tissues. Founded in 2013 and headquartered in Austin, Texas, the company was formerly known as Aeglea BioTherapeutics Holdings, LLC before changing its name in 2015.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.
Zikani Therapeutics, Inc. develops and commercializes therapeutics for patients with limited treatment options. It offers TURBO-ZM, a platform to develop novel ribosome modulating agents (RMAs) for the treatment of cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Zikani Therapeutics, Inc. was formerly known as Macrolide Pharmaceuticals, Inc. and changed its name to Zikani Therapeutics, Inc. in February 2015. Zikani Therapeutics, Inc. was incorporated in 2014 and is based in Watertown, Massachusetts.
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis.
Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.
Altimmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focused on developing innovative treatments for liver diseases, obesity, and immune modulation, alongside vaccines for infectious diseases. The company’s pipeline includes HepTcell, an immunotherapeutic candidate aimed at treating chronic hepatitis B, and pemvidutide, a dual GLP-1/glucagon receptor agonist designed for obesity and non-alcoholic steatohepatitis. Altimmune is also advancing several vaccine candidates, including NasoShield, an anthrax vaccine for intranasal administration, NasoVAX, a recombinant intranasal vaccine, and AdCOVID, a single-dose intranasal vaccine against COVID-19. In addition to its human health initiatives, the company is developing veterinary products and has established collaborations for technology development, notably with the University of Alabama at Birmingham for the AdCOVID project. Altimmune aims to address unmet medical and public health needs through its proprietary intranasal delivery technology and ongoing clinical research.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and neurodegenerative diseases that are influenced by the classical complement pathway. The company’s research revolves around C1q, a key molecule that, when aberrantly activated, contributes to various disease processes. Its lead product candidates include ANX005, a monoclonal antibody designed for intravenous administration, which has completed Phase 1b trials for treating Guillain-Barré syndrome, and ANX007, formulated for intravitreal use, which has also completed Phase 1b trials aimed at glaucoma treatment. Additionally, Annexon is advancing preclinical candidates targeting conditions such as warm autoimmune hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis, and geographic atrophy. Founded in 2011 and headquartered in South San Francisco, California, the company employs a biomarker-driven strategy to ensure effective engagement of its therapies in the intended patient populations.
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.
Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.
Quartet Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2013. It focuses on developing innovative treatments for chronic pain and inflammation by targeting the restoration of tetrahydrobiopterin (BH4) homeostasis in neuronal and inflammatory cells. Research indicates that increased levels of BH4 play a crucial role in managing peripheral nerve dysfunction and regulating immune cells. Founded by scientists from Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne, Quartet Medicine collaborates with various research partners in Europe and Asia to advance its therapeutic approaches. The company has attracted investment from notable firms, reflecting confidence in its mission to address significant health challenges associated with chronic pain.
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, founded in 2013. The company specializes in the tissue-specific regulation of sex hormone effects and is focused on developing innovative treatments for urological and endocrinological diseases. Its lead product, Fispemifene, is a selective estrogen receptor modulator designed to address symptoms related to low testosterone in men. Additionally, Forendo is working on a 17HSD1-inhibitor aimed at treating endometriosis. By targeting specific hormone mechanisms, Forendo Pharma seeks to enhance treatment options for both male and female health conditions, addressing unmet medical needs in these areas.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois.
Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative therapies aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology is designed to address a range of autoimmune and allergic diseases, including prevalent conditions such as celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens, Anokion’s approach provides precise therapies that minimize side effects and enhance patient outcomes in the treatment of autoimmune disorders.